Active Pharmaceutical Ingredient Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormones, Cytokines), Drug (OTC,Rx), Application (Diabetes, Oncology, CVD) & Region - Global Forecast to

The global active pharmaceutical ingredient market in terms of revenue was estimated to be worth $145.9 billion in 2022 and is poised to reach $216.4 billion by 2027, growing at a CAGR of 8.2% from 2022 to 2027.

The production capacity expansions by pharmaceutical and biopharmaceutical players, the growing importance of generics, and technological advancements in API manufacturing are some of the major factors driving the growth of this market. However, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years.

The prominent players in the active pharmaceutical ingredient market are Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and AstraZeneca plc (UK).

Get PDF Sample Report + All Related Table and Graphs @: https://www.reportspublisher.com/report/Active-Pharmaceutical-Ingredient-Market/request-sample

Opportunity: Emerging biosimilars market
The rising incidence of various diseases, the increasing number of off-patent biologic drugs, positive outcomes in ongoing clinical trials for biosimilars, and the rising demand for biosimilars in different therapeutic applications (such as rheumatoid arthritis and blood disorders) are the major factors driving the growth of the biosimilars market.

Biosimilars are generic versions of patented biologic drugs; hence, they do not need to comply with the stringent requirements of various regulatory authorities (making them cost-effective as compared to patented biologics). The expiration of patents and other intellectual property rights for originator biologics over the next decade is expected to open up opportunities for biosimilars to enter the market.

Based on the type of drug, the APIs market can be classified into two segments: prescription drugs and over-the-counter (OTC) drugs. The prescription drugs segment accounted for the largest share of the APIs market. Since the majority of the drugs are sold only with a doctor's prescription, the demand for APIs for manufacturing such drugs is the highest. Rising innovator drugs can also be attributed to the growing demand for APIs in the prescription drug segment. Additionally, government initiatives to make drugs affordable and the rise of generics will attribute to the larger share of this segment.

The prescription drugs segment is expected to account for the largest share of the active pharmaceutical ingredient market.

Interested in Purchasing this Report? Click here @ https://www.reportspublisher.com/checkout?report=RP-205855&type=single

Based on the type of drug, the APIs market can be classified into two segments: prescription drugs and over-the-counter (OTC) drugs. The prescription drugs segment accounted for the largest share of the APIs market. Since the majority of the drugs are sold only with a doctor's prescription, the demand for APIs for manufacturing such drugs is the highest. Rising innovator drugs can also be attributed to the growing demand for APIs in the prescription drug segment. Additionally, government initiatives to make drugs affordable and the rise of generics will attribute to the larger share of this segment.

The mammalian expression systems segment is expected to account for the largest share of the biotech active pharmaceutical ingredient market
On the basis of the expression system, biotech APIs can be categorised into mammalian expression systems, microbial expression systems, yeast expression systems, insect expression systems, and other expression systems.

North America is expected to account for the largest size of active pharmaceutical ingredient market during the forecast period.

The study categorizes the active pharmaceutical ingredient market based on following segments and sub-segments

By Type
• Innovative APIs
• Generic APIS

By Potency
• Traditional API
• HPAPI

By Type of Synthesis
• Synthetic APIs Market
Synthetic APIs, by Type
• Innovative Synthetic APIs
• Generic Synthetic APIs
• Biotech APIs Market

Get Customized report at https://www.reportspublisher.com/report/Active-Pharmaceutical-Ingredient-Market/request-customization

Biotech APIs, by Type
• Innovative Biotech APIs
• Generic Biotech APIs

Biotech APIs, by Product
• Monoclonal Antibodies
• Hormones and Growth Factors
• Cytokines
• Fusion Proteins
• Therapeutic Enzymes
• Recombinant Vaccines
• Blood Factors

Biotech APIs, by Expression System
• Mammalian Expression Systems
• Microbial Expression Systems
• Yeast Expression Systems
• Insect Expression Systems
• Other Expression Systems

By Type of Drug
• Prescription Drugs
• Over-the-counter Drugs

By Therapeutic Application
• Communicable Diseases
• Oncology
• Diabetes
• Cardiovascular Diseases
• Pain Management
• Respiratory Diseases
• Other Therapeutic Applications

Alex
USA Office
1050 West Lakes Drive, West Covina,
California 91790, Los Angeles, United States
E-mail: help@reportspublisher.com
Phone: +1-323-982-8916

REPORTS PUBLISHER is a market research and consultative company that provides market research reports and business insights to large and small & medium enterprises. The company supports its clients to conceive business policies and accomplish sustainable growth in their particular market domain.

This release was published on openPR.